대한뉴팜

Daehan New Pharm has recorded a 23% year-over-year growth rate in the obesity treatment market, continuing to strengthen its leadership position.

The company has achieved sustained annual sales growth of over 20% for the past three years, driven by the continued launch of reimbursable products, increased market share of oral obesity drugs, and expansion into the non-reimbursable injectable treatment segment. Among these, oral obesity drugs have shown particularly steady growth.

Daehan New Pharm’s representative oral anti-obesity products include appetite suppressants such as Phentin (Phendimetrazine), Phestin (Phentermine), and Phtym (Phentermine HCl), as well as the fat absorption inhibitor Zerofat (Orlistat), which the company co-markets with Mothers Pharmaceutical. In addition, Daehan New Pharm offers a wide range of obesity-related therapeutic products, collectively accounting for over 40% of the anti-obesity drug market share.

Following a decline in obesity surgeries such as gastric banding and sleeve gastrectomy after the Shin Hae-chul incident, interest in combined pharmacological and exercise-based therapies has grown. As a result, the oral obesity drug market has steadily expanded, reaching approximately 100 billion KRW in 2016 according to IMS data, and continues to show growth momentum.

Although newer drugs such as Belviq (Ildong Pharmaceutical) and Contrave (Kwangdong Pharmaceutical) have contributed to market expansion, traditional appetite suppressants containing phendimetrazine or phentermine and fat absorption inhibitors still hold a dominant share of the obesity market. Utilizing its extensive experience in obesity prescription marketing, Daehan New Pharm continues to expand its trading network and revenue. The company has also developed therapeutics to alleviate side effects associated with oral obesity medications, driving rapid sales growth.

In the first half of this year, Daehan New Pharm’s oral obesity drug sales achieved an impressive 23% increase compared to the same period last year. Moving forward, the company plans to further strengthen brand recognition for products such as Phentin, Fastin, and Topin and expand its market share through its 3S strategy—self-control, self-confidence, and satisfaction—designed to meet the needs of both customers and patients.